Founded in 1968, Sichuan Long March Pharmaceutical Co., Ltd. is located in Leshan City, a famous historical and cultural city in Southwest Sichuan Province. Long March, directly controlled by Sichuan Lanyan Investment Group Co., Ltd. (hereinafter referred to Lanyan Group), is a large antibiotic API production enterprise in Southwest China, which is the core enterprise of key medical pharmaceutical industry of Lanyan Group.
    With more than 50 years’ experience in production and operation since its establishment, Long March has been in strict accordance with the national industrial policy and the production and operation regulations of the pharmaceutical industry, adhering to the business philosophy of responsibility, quality, integrity and innovation, taking the construction of modern medical and pharmaceutical enterprise as the development goal, and constantly growing and developing. The company's business scope covers biological fermentation, chemical synthesis, pharmaceutical machinery and other fields, with more than 100 products. The main API products are sold to 63 countries and regions such as the United States, Europe, Japan, Australia, Africa and Southeast Asia. The CY and Shanjiang trademarks are well-known at home and abroad. The company has multiple production lines which have passed the GMP certification inspection in China. In 1982, the company took the lead in China and passed the FDA certification inspection for 14 consecutive times. Eight products were approved to enter the U.S. market successively. At the same time, it took the lead in successfully registering in the European Union in 2002 and passed the EDQM certification inspection for three times in a row. The company has been awarded Sichuan Enterprise Technology Center and Sichuan Advanced Antibiotic R&D and Production Base by the People's Government of Sichuan Province, and has developed one national first class new drug, one third class new drug and one fifth class new drug; The company has one national invention patent and participated in the formulation of Pharmacopoeia standards for many products.
    In order to consolidate the core foundation of the pharmaceutical section of Lanyan group and implement the strategic development plan of seamless joint relocation of the company, the New Long March Pharmaceutical Park of Lanyan started construction in Leshan industrial concentration zone in 2011, covering an area of 800 mu(a unit of area ,1 mu equals to 0.0667 hectares), which is a key construction project of Leshan City. The first phase of the project has been completed in 2013, with the production capacity of 500 million water injections, 500 million capsules and 1.5 billion tablets per year. All production lines in phase I have passed the GMP certification and inspection of China. The second phase project is designed to produce 3000 tons of fermentation APIs and 200 tons of synthetic APIs. After the project is put into operation in stages, it is expected that the annual output value will reach 1billion yuan and the total profit and tax will reach 150 million yuan, which will create greater economic and social benefits.